La Jolla Pharmaceutical Company (NASDAQ:LJPC) was founded in 1989 and is headquartered in San Diego, California, with 169 full-time employees. It is a biopharmaceutical company focusing on the discovery, development and development of treatment methods for life-threatening diseases. commercialize.
La Jolla Pharmaceutical Company (LJPC):
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, aiming to significantly improve the prognosis of patients with life-threatening diseases.
La Jolla Pharmaceuticals offers GIAPREZA, an intravenous injection used to increase blood pressure in adults with sepsis or other distributive shock.
La Jolla Pharmaceuticals is also developing LJPC-401 hepcidin, a formulation of synthetic human hepcidin, for the treatment of diseases characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and Myelodysplastic syndrome.
La Jolla Pharmaceutical Company is also developing:
- LJPC-501, an angiotensin II, is used for the potential treatment of anti-catecholamine hypotension and hepatorenal syndrome;
- GCS-100, a galectin-3 inhibitor, is used for the potential treatment of chronic kidney disease;
- LJPC-1010 galectin-3 inhibitor, a potential treatment drug for other disease characteristics such as non-alcoholic steatohepatitis (NASH) and tissue fibrosis.
Stock price changes:
On June 6, 2019, La Jolla Pharmaceuticals announced the positive results of the preliminary interim analysis of the Phase II study of LJPC-401 in patients with hereditary hemochromatosis. The company’s stock price soared more than doubled, and as of the day’s close, it was still up 92 %.